Trials in Philadelphia, Pennsylvania
Here are the top 10 medical studies for breast cancer in Philadelphia, Pennsylvania
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
Sacituzumab Govitecan for Triple-Negative Breast Cancer
Recruiting4 awardsPhase 3
New Brunswick, New Jersey
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Monoclonal Antibodies
Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Breast Cancer
Recruiting4 awardsPhase 3
Hamilton, New Jersey
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Antibody-drug conjugate
Dato-DXd for Triple-negative Breast Cancer
Recruiting2 awardsPhase 3
Florham Park, New Jersey
This trial is testing a new drug called Dato-DXd to see if it works better than current treatments for patients with a specific type of breast cancer that has come back or spread and cannot be treated with certain common therapies. The drug aims to target and kill cancer cells more effectively.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant for Early Breast Cancer
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
PI3K/mTOR Inhibitor
Gedatolisib + Fulvestrant +/- Palbociclib for Advanced Breast Cancer
Recruiting2 awardsPhase 3
Horsham, Pennsylvania
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
Antibody-drug conjugate
Dato-DXd +/− Durvalumab for Breast Cancer
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is testing a new treatment for patients with a specific type of breast cancer who still have cancer after surgery and initial treatments. The treatment uses a drug called Dato-DXd, which targets and kills cancer cells, and may also include durvalumab, which helps the immune system fight cancer. The goal is to see if this new treatment works better than current options.
Trials With No Placebo
Cardiometabolic Screening for Breast Cancer Survivors
Recruiting1 award4 criteria
Baltimore, Maryland
This trial is testing a screening program to catch early signs of diabetes, high cholesterol, and other heart disease risk factors in breast cancer survivors. The goal is to get patients help and treatment before these conditions worsen.
Monoclonal Antibodies
Sacituzumab Govitecan for Triple-Negative Breast Cancer
Recruiting4 awardsPhase 3
New Brunswick, New Jersey
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Monoclonal Antibodies
Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Breast Cancer
Recruiting4 awardsPhase 3
Hamilton, New Jersey
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Monoclonal Antibodies
XMT-1660 for Breast Cancer
Recruiting1 awardPhase 1
New York, New York
This trial tests a new drug called XMT-1660 to see if it is safe and what side effects it might have. It focuses on patients whose cancer has come back, spread locally, or spread throughout the body. The study will first find a safe dose and then check if this dose helps treat solid tumors.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.